+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893206
Description Jump to:
The global hereditary angioedema therapeutic market size is expected to reach USD 5.8 billion by 2030., exhibiting a 7.4% CAGR from 2023 to 2030. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China’s National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Hereditary Angioedema Therapeutics Market Report Highlights

  • The C1-esterase inhibitor segment held the largest share in 2022 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
  • On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
  • North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2022. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
  • Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
  • Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Treatment
1.1.2. End-use
1.1.3. Route of administration
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment outlook
2.2.2. End-use outlook
2.2.3. Route of administration outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Hereditary Angioedema Therapeutic Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Hereditary Angioedema Therapeutic Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Hereditary Angioedema Therapeutic Market: Treatment Estimates & Trend Analysis
4.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
4.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
4.3. C1-esterase Inhibitor
4.3.1. C1-esterase inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
4.4. Bradykinin B2 Receptor Antagonist
4.4.1. Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 to 2030, (USD Million)
4.5. Kallikrein Inhibitor
4.5.1. Kallikrein inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
4.6. Others
4.6.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 5. Hereditary Angioedema Therapeutic Market: End-use Estimates & Trend Analysis
5.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
5.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Prophylaxis
5.3.1. Silicon market estimates and forecasts, 2018 to 2030, (USD Million)
5.4. On-demand
5.4.1. Metal market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 6. Hereditary Angioedema Therapeutic Market: Route of Administration Estimates & Trend Analysis
6.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
6.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Intravenous
6.3.1. Intravenous market estimates and forecasts, 2018 to 2030, (USD Million)
6.4. Subcutaneous
6.4.1. Subcutaneous market estimates and forecasts, 2018 to 2030, (USD Million)
6.5. Oral
6.5.1. Oral market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 7. Hereditary Angioedema Therapeutic Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Hereditary Angioedema Therapeutic Market by Region: Key Takeaways
7.3. North America
7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. BioCryst Pharmaceuticals, Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Ionis Pharmaceuticals
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. CSL
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Attune Pharmaceuticals
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Adverum Biotechnologies, Inc.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. KalVista Pharmaceuticals, Inc.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Takeda Pharmaceutical Company Limited
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Pharming
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiative
List of Tables
Table 1 List of Abbreviations
Table 2 North America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 3 North America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 4 North America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 5 North America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 7 U.S. hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 8 U.S. hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 9 Canada hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 10 Canada hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 11 Canada hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 12 Europe hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 13 Europe hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 14 Europe hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 15 Europe hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
Table 16 Germany hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 17 Germany hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 18 Germany hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 19 UK hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 20 UK hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 21 UK hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 22 France hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 23 France hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 24 France hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 25 Italy hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 26 Italy hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 27 Italy hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 28 Spain hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 29 Spain hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 30 Spain hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
Table 31 Denmark hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 32 Denmark hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 33 Denmark hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 34 Sweden hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 35 Sweden hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 36 Sweden hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 37 Norway hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 38 Norway hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 39 Norway hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 40 Asia Pacific hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 41 Asia Pacific hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 42 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 43 Asia Pacific hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
Table 44 Japan hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 45 Japan hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 46 Japan hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
Table 47 China hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 48 China hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 49 China hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 50 India hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 51 India hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 52 India hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
Table 53 Australia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 54 Australia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 55 Australia hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
Table 56 Thailand hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 57 Thailand hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 58 Thailand hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 59 South Korea hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 60 South Korea hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 61 South Korea hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 62 Latin America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 63 Latin America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 64 Latin America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 65 Latin America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 67 Brazil hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 68 Brazil hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 69 Mexico hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 70 Mexico hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 71 Mexico hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 72 Argentina hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 73 Argentina hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 74 Argentina hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 80 South Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 81 South Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 85 UAE hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 86 UAE hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 87 UAE hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 88 Kuwait hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
Table 89 Kuwait hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
Table 90 Kuwait hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Hereditary angioedema therapeutics: Market outlook
Fig. 9 Hereditary angioedema therapeutics: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Hereditary angioedema therapeutics market driver impact
Fig. 15 Hereditary angioedema therapeutics market restraint impact
Fig. 16 Hereditary angioedema therapeutics market strategic initiatives analysis
Fig. 17 Hereditary angioedema therapeutics market: Treatment movement analysis
Fig. 18 Hereditary angioedema therapeutics market: Treatment outlook and key takeaways
Fig. 19 C1-esterase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Kallikrein inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Hereditary angioedema therapeutics market: End-use movement analysis
Fig. 24 Hereditary angioedema therapeutics market: End-use outlook and key takeaways
Fig. 25 Prophylaxis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 On-demand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Hereditary angioedema therapeutics market: Route of administration movement analysis
Fig. 28 Hereditary angioedema therapeutics market: Route of administration outlook and key takeaways
Fig. 29 Intravenous market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Subcutaneous market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Global hereditary angioedema therapeutics market: Regional movement analysis
Fig. 33 Global hereditary angioedema therapeutics market: Regional outlook and key takeaways
Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals
  • CSL
  • Attune Pharmaceuticals
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Pharming

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 3.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.8 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Global Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type (On-Demand, Prophylaxis), Route Of Administration - Forecast 2024-2030 - Product Image

Global Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type (On-Demand, Prophylaxis), Route Of Administration - Forecast 2024-2030

  • Report
  • 190 Pages
  • Global
From
Hereditary Angioedema Therapeutics Global Market Report 2024 - Product Image

Hereditary Angioedema Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Hereditary Angioedema Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Hereditary Angioedema Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 180 Pages
  • Global
From
Global Hereditary Angioedema Therapeutics Market 2023-2027 - Product Image

Global Hereditary Angioedema Therapeutics Market 2023-2027

  • Report
  • 156 Pages
  • Global
From
Global Psoriatic Arthritis Treatment Market Report and Forecast 2023-2031 - Product Image

Global Psoriatic Arthritis Treatment Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.